The Sly Oncogene: FOXA1 Mutations in Prostate Cancer

Neel Shah¹, Myles Brown²

Affiliations

¹ Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
² Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Electronic address: myles_brown@dfci.harvard.edu.

PMID: 31408618
DOI: 10.1016/j.ccell.2019.07.005

Free article

Comment

The Sly Oncogene: FOXA1 Mutations in Prostate Cancer

Neel Shah et al. Cancer Cell. 2019.

Free article

. 2019 Aug 12;36(2):119-121.

doi: 10.1016/j.ccell.2019.07.005.

Authors

Neel Shah¹, Myles Brown²

Affiliations

¹ Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
² Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Electronic address: myles_brown@dfci.harvard.edu.

PMID: 31408618
DOI: 10.1016/j.ccell.2019.07.005

Abstract

FOXA1 mutations occur frequently in prostate cancer and are associated with a worse clinical outcome. However, the mechanism by which these mutations act was until now largely unknown. Two recent publications clearly demonstrate that FOXA1 acts as an oncogene in prostate cancer and delineate the phenotypic effects of distinct classes of FOXA1 alterations.

PubMed Disclaimer

Comment on

FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes.
Adams EJ, Karthaus WR, Hoover E, Liu D, Gruet A, Zhang Z, Cho H, DiLoreto R, Chhangawala S, Liu Y, Watson PA, Davicioni E, Sboner A, Barbieri CE, Bose R, Leslie CS, Sawyers CL. Adams EJ, et al. Nature. 2019 Jul;571(7765):408-412. doi: 10.1038/s41586-019-1318-9. Epub 2019 Jun 26. Nature. 2019. PMID: 31243370 Free PMC article.
Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer.
Parolia A, Cieslik M, Chu SC, Xiao L, Ouchi T, Zhang Y, Wang X, Vats P, Cao X, Pitchiaya S, Su F, Wang R, Feng FY, Wu YM, Lonigro RJ, Robinson DR, Chinnaiyan AM. Parolia A, et al. Nature. 2019 Jul;571(7765):413-418. doi: 10.1038/s41586-019-1347-4. Epub 2019 Jun 26. Nature. 2019. PMID: 31243372 Free PMC article.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

The Sly Oncogene: FOXA1 Mutations in Prostate Cancer

Affiliations

The Sly Oncogene: FOXA1 Mutations in Prostate Cancer

Authors

Affiliations

Abstract

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical